Table 1.

Ranges of percentage of EM isolates susceptible to each antibiotic from 4 long-term clinical investigations [1, 3, 4, 6, 10].

Antibiotics	Ranges of	References
	susceptible isolates (%)
Ciprofloxacin	43.4–91.7	[1, 3, 4, 6]
Levofloxacin	62.5–81.8	[1, 3, 4, 6, 10]
Gatifloxacin	65.4–100	[6, 8]
Garenoxacin	100	[6]
Moxifloxacin	87.9	[4]
Piperacillin tazobactam	11.5–90.6	[3, 4, 6, 10]
Ticarcillin-clavulanate	78.8	[4]
Trimethoprim sulfamethoxazole	65–96.9	[1, 3, 4, 6]
Rifampin	69.2–93	[1, 6, 10]
Cefepime	0–100	[3, 4, 6]
Ceftazidime	0–34.6	[3, 4, 6, 10]
Aztreonam	0–11.5	[3, 10]
Imipenem	0–34.6	[3, 4, 6, 10]
Meropenem	0–34.6	[4, 6, 10]
Vancomycin	0–65	[1, 3, 4, 6]
Amikacin	0–21.2	[3, 4, 6]
Gentamicin	16.7–18.2	[4, 6]
Colistin	0	[3, 4]
Tigecycline	32.3–84.4	[3, 4]
Doxycycline	78.8	[4]